⌘K

OrbiMed logo

OrbiMed

Crunchbase
Pitchbook
Crunchbase

Deals on record

30

Common Fundraising Type

Series A

Curevo logo
Curevo

Biotechnology • Vaccines

Medicxi logo
Sanofi Ventures logo
RA Capital Management logo
OrbiMed logo

Curevo is a biotechnology company focused on developing vaccines with improved tolerability and accessibility, currently advancing a shingles vaccine called amezosvatein.

Series B
$110M
03/17/2025
Article
Garuda Therapeutics logo
Garuda Therapeutics

Hematopoietic • Stem Cell

Garuda Therapeutics develops proprietary hematopoietic stem cell therapies that are self-renewing, HLA-compatible, and transgene-free for immediate patient availability.

Series A
$50M
03/04/2025
Article
Pulnovo Medical logo
Pulnovo Medical

Medtech • Pulmonary hypertension

Qiming Venture Partners logo
OrbiMed logo
Lilly Asia Ventures logo
Gaorong Capita logo

Pulnovo Medical develops medical devices for treating pulmonary hypertension and heart failure, with a focus on their PADN technology.

Series C
$100M
03/03/2025
Article
Helicore Biopharma logo
Helicore Biopharma

Biopharma • Obesity Treatment

Versant Ventures logo
Wellington Management logo
OrbiMed logo
Longitude Capital logo

Helicore Biopharma develops glucose-dependent insulinotropic peptide (GIP) antagonist therapies for obesity treatment.

Series A
$65M
02/13/2025
Article
Windward Bio logo
Windward Bio

Drug development • Respiratory conditions

Novo Holdings logo
OrbiMed logo
RTW Investments logo
Qiming Venture Partners logo

Windward Bio is a clinical-stage drug development company focused on creating treatments for severe respiratory conditions, including asthma and COPD, using long-acting monoclonal antibodies and bispecifics.

Series A
$200M
01/10/2025
Article
Verdiva Bio logo
Verdiva Bio

Biopharmaceutical • Obesity

General Atlantic logo
Forbion logo
RA Capital Management logo
OrbiMed logo

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Series A
$411M
01/09/2025
Article
Aviceda Therapeutics logo
Aviceda Therapeutics

Biotech • Immunomodulators

TCGX logo
Omega Funds logo
Jeito Capital logo
Enavate Sciences logo

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOSâ„¢ nanotechnology platform.

Series C
$207.5M
01/07/2025
Article
SiteOne Therapeutics logo
SiteOne Therapeutics

Biopharmaceutical • Ion Channel Modulators

Novo Holdings logo
OrbiMed logo
Mission BioCapital logo
Wellington Management logo

SiteOne Therapeutics is a biopharmaceutical company developing selective, small molecule ion channel modulators for treating sensory hyperexcitability disorders like pain and chronic cough.

Series C
$100M
12/18/2024
Article
Angitia Biopharmaceuticals logo
Angitia Biopharmaceuticals

Biotechnology • Clinical-stage

Yonghua Capital logo
OrbiMed logo
Legend Capital logo
Janus Henderson logo

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel treatments for serious musculoskeletal diseases.

Series C
$120M
12/11/2024
Article
Adcendo logo
Adcendo

Biotech • Antibody-Drug Conjugates

TCGX logo
Ysios Capital logo
Venrock Healthcare Capital Partners logo
Surveyor Capital logo

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Series B
$135M
11/25/2024
Article
Avenzo Therapeutics logo
Avenzo Therapeutics

Biotechnology • Oncology

TF Capital logo
Surveyor Capital logo
SR One logo
Sofinnova Investments logo

Avenzo Therapeutics is a biotechnology company developing oncology therapies, including a CDK2 inhibitor for advanced solid tumors and HR+/HER2-negative metastatic breast cancer.

Series A
Undisclosed
11/19/2024
Article
Alentis Therapeutics logo
Alentis Therapeutics

Biotech • Clinical-stage

Jeito Capital logo
Novo Holdings logo
OrbiMed logo
RA Capital Management logo

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Series D
$181.4M
11/12/2024
Article
Leal Therapeutics logo
Leal Therapeutics

Biotechnology • Central Nervous System

Chugai Venture Fund logo
Newpath Partners logo
PhiFund logo
OrbiMed logo

Leal Therapeutics is a biotechnology company developing treatments for central nervous system disorders, focusing on amyotrophic lateral sclerosis (ALS) and schizophrenia.

Equity
$45M
10/30/2024
Article
Triveni Bio logo
Triveni Bio

Biotech • Antibody treatments

Goldman Sachs Alternatives logo
Viking Global Investors logo
OrbiMed logo
Invus logo

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series B
$115M
10/02/2024
Article
Candid Therapeutics logo
Candid Therapeutics

Biotechnology • Autoimmune therapies

Venrock Healthcare Capital Partners logo
Vida Ventures logo
TCGX logo
Third Rock Ventures logo

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Equity
$370M
09/09/2024
Article
Odyssey Therapeutics logo
Odyssey Therapeutics

Biotechnology • Immunomodulators

Woodline Partners logo
Walleye Capital logo
Leerink Partners logo
The Global BioAccess Fund logo

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Series C
$101M
12/05/2023
Article
Koya Medical logo
Koya Medical

Healthcare • Lymphedema Treatment

OrbiMed logo

Koya Medical develops innovative treatments for lymphedema and other venous diseases, aiming to provide personalized care for patients suffering from these debilitating conditions.

Equity
$30M
11/15/2023
Article
Forward Therapeutics logo
Forward Therapeutics

Biotechnology • Immune Therapies

RA Capital Management logo
OrbiMed logo
BVF Partners logo

Forward Therapeutics is a company focused on advancing the development of next-generation small molecule immune therapies.

Series A
$50M
11/08/2023
Article
Terremoto Biosciences logo
Terremoto Biosciences

Biotechnology • Disease Targeting

Third Rock Ventures logo
OrbiMed logo
Novo Holdings logo
EcoR1 Capital logo

Terremoto Biosciences is a biotechnology company that has raised $175 million in a Series B financing round to advance its platform and support the development of multiple in-house programs targeting diseases of high unmet medical need.

Series B
$175M
11/02/2023
Article
Triveni Bio logo
Triveni Bio

Biotech • Antibody treatments

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series A
$92M
10/26/2023
Article
Rampart Bioscience logo
Rampart Bioscience

Biotechnology • Gene Therapy

OrbiMed logo
Forbion logo
RA Capital Management logo
HealthCap logo

Rampart Bioscience is a biotechnology company developing next-generation biologics using their proprietary DNA-based medicines platform, HALO, with a focus on treating hypophosphatasia.

Series A
$85M
10/24/2023
Article
MinervaX logo
MinervaX

Biotechnology • Maternal Vaccines

EQT Life Sciences logo
OrbiMed logo
Novo Holdings logo
Pureos Ventures logo

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.

Equity
$57.3M
10/11/2023
Article

Series B
$100M
10/03/2023
Article
Evozyne logo
Evozyne

Biotech • Drug Discovery

Valor Equity Partners logo
Paragon Biosciences logo
OrbiMed logo
NVentures logo

Evozyne is a biotech company that uses generative AI to discover new drugs and develop gene editors and enzymes that modulate immune response, with a focus on addressing therapeutic challenges and sustainability issues.

Series B
$81M
09/27/2023
Article
Adela logo
Adela

Blood Testing • Cancer Detection

RA Capital Management logo
OrbiMed logo
Labcorp logo
F-Prime Capital logo

Adela is a healthcare technology company that specializes in blood testing for early cancer detection and minimal residual disease monitoring using a genome-wide methylome enrichment platform.

Equity
$48M
09/26/2023
Article
ReCode Therapeutics logo
ReCode Therapeutics

Genetic Medicines • MRNA Therapeutics

Bioluminescence Ventures logo
Solasta Ventures logo
Sanofi Ventures logo
Pfizer Ventures logo

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

Series B
$50M
09/19/2023
Article
Corteria Pharmaceuticals logo
Corteria Pharmaceuticals

Biopharmaceuticals • Cardiovascular Therapies

OrbiMed logo
Jeito Capital logo
V-Bio Ventures logo
Omnes Capital logo

Corteria Pharmaceuticals is a biopharmaceutical company that develops first-in-class therapies for unaddressed heart failure subpopulations, with a focus on multi-organ benefits targeting the kidneys, heart, and vessels.

Series A
$69.6M
09/07/2023
Article
Star Therapeutics logo
Star Therapeutics

Biotechnology • Antibody Therapies

Sofinnova Investments logo
Westlake Village BioPartners logo
OrbiMed logo
Redmile Group logo

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

Series C
$90M
09/05/2023
Article
Epigenic Therapeutics logo
Epigenic Therapeutics

Biotechnology • Gene Editing

Qiming Venture Partners logo
OrbiMed logo
Morningside Venture Capital logo

Epigenic Therapeutics is a biotechnology company that develops gene editing therapies for various diseases using its proprietary technology platform, EPIREG, which optimizes CRISPR-Cas components for gene regulation without altering DNA sequences and employs a proprietary lipid nanoparticle medicine delivery system.

Series A
$32M
08/30/2023
Article
FORE Biotherapeutics logo
FORE Biotherapeutics

Precision Oncology • Clinical Development

SR One logo
Medicxi logo
Wellington Management logo
Samsung Securities logo

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.

Series D
$75M
08/23/2023
Article